Answers are grounded in this paper and cite their sources.
Foot-and-mouth disease (FMD) remains a major burden in endemic regions, where inactivated vaccines are constrained by cost, short duration of immunity, cold-chain dependence, and high-containment manufacturing. Here, we engineered a recombinant bovine papular stomatitis virus (rBPSV) expressing the FMDV A24 Cruzeiro capsid precursor P1-2A together with an attenuated 3C protease (3C pro L127P ). Infection of ovine fetal turbinate (OFTu) cells resulted in robust capsid protein expression and assembly of abundant 25-30 nm icosahedral virus-like particles (VLPs). Intramuscular immunization of two BPSV-seropositive calves with rBPSV (10 7 TCID 50 on days 0, 21 and 35) induced strong anti-FMDV humoral responses. By day 28, liquid-phase blocking ELISA (LPBE) titers exceeded laboratory defined protective threshold (≥1.9 log 10 ), and homologous neutralizing titers against A24 Cruzeiro surpassed the threshold associated with protection (≥1.36 log 10 ). Intra-serotypic cross-neutralization was observed against A/Argentina/2001, whereas no neutralization was detected against heterologous serotype O 1 Campos. Pre-existing anti-BPSV antibodies did not prevent induction of neutralizing responses. These findings establish first proof-of-concept that BPSV can serve as a cattle-adapted vector platform for delivery of FMDV VLPs and other heterologous antigens.
No takes yet. Share an insight, caveat, or question.
Chambaro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: